Lumida
/GL
⌘K
Globe Life Inc

Globe Life Inc

GL
$171.17USD↑+0.22%+0.37 today

MARKET CAP

13.2B

P/E (TTM)

12.1x

FWD P/E

—

DAY RANGE

$171 – $174

52W RANGE

$128
$192

AI Summary

Stalk
TrimMedium

GL is in a Stage 4 distribution phase with active Lower Highs & Lower Lows confirming supply dominance and a bearish medium-term bias. Short-term timing is unfavorable as price trades below declining EMAs in an oversold context without any reversal signals. Execution should be deferred, trimming into rallies near the 9/20 EMA resistance zone around 172–174. The long-term uptrend remains intact above the 200-day SMA, providing structural support unless decisively broken.

  • ↑Q2 2026 net income rose 20% YoY to $288M, driven by 16% health premium growth ($437M).
  • ↑Management forecasts ~7% total premium revenue growth in 2026, underscoring durable momentum.
  • ↓Negative growth outlook as admin expenses rise 8% YoY and investment income falls 8% to $31M.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Globe Life Inc. (NYSE: GL) is a prominent provider of life and health insurance products, primarily targeting lower middle to middle-income demographics in the United States. The company operates multiple brands including American Income Life, Liberty National, and United American, which enable them to effectively leverage a broad distribution network. Globe Life's strategic focus on serving an underserved market allows it to capitalize on increasing demand for basic insurance coverage, especially as many individuals remain underinsured.

Bull says

  • ↑Q2 2026 net income rose 20% YoY to $288M, driven by 16% health premium growth ($437M).
  • ↑Management forecasts ~7% total premium revenue growth in 2026, underscoring durable momentum.
  • ↑Accelerated buybacks of $670–700M for 2026 support EPS outlook of $15.55–15.95.
  • ↑AI-driven efficiency initiatives aim to boost sales conversion and lower operating costs.
  • ↑Mid-single-digit agent count growth expected in H2 2026, backed by a strong recruitment pipeline.
  • ↑Underserved low-middle income market share and positive momentum factors underpin long-term growth.

Bear says

  • ↓Negative growth outlook as admin expenses rise 8% YoY and investment income falls 8% to $31M.
  • ↓Sales growth may slow during new agent onboarding, per management guidance.
  • ↓High agent turnover and lower productivity risk weakening future sales.
  • ↓Rising lapse rates amid macro stress could erode revenue and underwriting margins.
  • ↓Heavy administrative expenses and ongoing buybacks could strain cash flow and dividends.
  • ↓Unfavorable revisions and liquidity factor concerns highlight balance sheet and growth risks.

Investment themes with GL

L&H Insurance↓ -0.09%

PGR · TRV · ALL

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-19-2026neutral

Transcript signals

Bull points

  • Net operating income for the quarter was $271 million, or $3.27 per share, an increase of 10% over the $2.97 per share from a year ago.
  • In our life insurance operations, Premium revenue for the second quarter increased 3% from the year-ago quarter to $840 million. Life underwriting margin was $340 million, up 6% from a year ago, driven by premium growth and lower overall policy obligations.
  • For the year, we expect health premium revenue to grow in the range of 8 to 9 percent and anticipate health underwriting margin as a percent of premium to be between 25 and 27%.

Bear points

  • Excess investment income, which we define as net investment income less only required interest, was $35 million, down approximately $8 million from the year-ago quarter.
  • For the full year 2025, we expect net investment income to be up about 1% and required interest to grow around 2.5%, resulting in a decline in excess investment income of around 10% to 15% for the year.
  • For the full year 2025, we expect net investment income to be up about 1% and required interest to grow around 2.5%, resulting in a decline in excess investment income of around 10% to 15% for the year.
Read full transcript analysis ›